Emerging targets for hematological malignancies

Daniela Cilloni, Francesco Frassoni, Giuseppe Saglio

Research output: Contribution to journalArticle

Abstract

Molecularly targeted therapies have been increasingly incorporated into standard treatment regimens for the majority of hematological malignancies. To increase the efficacy of the next generation of drugs, research efforts have been aimed at identifying molecular defects specific to leukemic cells. A significant therapeutic opportunity is represented by the possibility of selectively eradicating the leukemic stem cell pool. This review focuses on new insights regarding oncogenetic mechanisms in hematological malignancies and related possible druggable targets, including the pathways leading to leukemic stem cell maintenance and the specific approaches used to eliminate them.

Original languageEnglish
Pages (from-to)548-558
Number of pages11
JournalCurrent Opinion in Drug Discovery and Development
Volume13
Issue number5
Publication statusPublished - Sep 2010

Fingerprint

Hematologic Neoplasms
Stem Cells
Maintenance
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Bcl-2
  • hematological malignancy
  • hematopoietic stem cell
  • kinase inhibitor
  • leukemic stem cell
  • transcription factor

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Emerging targets for hematological malignancies. / Cilloni, Daniela; Frassoni, Francesco; Saglio, Giuseppe.

In: Current Opinion in Drug Discovery and Development, Vol. 13, No. 5, 09.2010, p. 548-558.

Research output: Contribution to journalArticle

Cilloni, Daniela ; Frassoni, Francesco ; Saglio, Giuseppe. / Emerging targets for hematological malignancies. In: Current Opinion in Drug Discovery and Development. 2010 ; Vol. 13, No. 5. pp. 548-558.
@article{7b84ac7989ae4467a1488df88764aa96,
title = "Emerging targets for hematological malignancies",
abstract = "Molecularly targeted therapies have been increasingly incorporated into standard treatment regimens for the majority of hematological malignancies. To increase the efficacy of the next generation of drugs, research efforts have been aimed at identifying molecular defects specific to leukemic cells. A significant therapeutic opportunity is represented by the possibility of selectively eradicating the leukemic stem cell pool. This review focuses on new insights regarding oncogenetic mechanisms in hematological malignancies and related possible druggable targets, including the pathways leading to leukemic stem cell maintenance and the specific approaches used to eliminate them.",
keywords = "Bcl-2, hematological malignancy, hematopoietic stem cell, kinase inhibitor, leukemic stem cell, transcription factor",
author = "Daniela Cilloni and Francesco Frassoni and Giuseppe Saglio",
year = "2010",
month = "9",
language = "English",
volume = "13",
pages = "548--558",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Emerging targets for hematological malignancies

AU - Cilloni, Daniela

AU - Frassoni, Francesco

AU - Saglio, Giuseppe

PY - 2010/9

Y1 - 2010/9

N2 - Molecularly targeted therapies have been increasingly incorporated into standard treatment regimens for the majority of hematological malignancies. To increase the efficacy of the next generation of drugs, research efforts have been aimed at identifying molecular defects specific to leukemic cells. A significant therapeutic opportunity is represented by the possibility of selectively eradicating the leukemic stem cell pool. This review focuses on new insights regarding oncogenetic mechanisms in hematological malignancies and related possible druggable targets, including the pathways leading to leukemic stem cell maintenance and the specific approaches used to eliminate them.

AB - Molecularly targeted therapies have been increasingly incorporated into standard treatment regimens for the majority of hematological malignancies. To increase the efficacy of the next generation of drugs, research efforts have been aimed at identifying molecular defects specific to leukemic cells. A significant therapeutic opportunity is represented by the possibility of selectively eradicating the leukemic stem cell pool. This review focuses on new insights regarding oncogenetic mechanisms in hematological malignancies and related possible druggable targets, including the pathways leading to leukemic stem cell maintenance and the specific approaches used to eliminate them.

KW - Bcl-2

KW - hematological malignancy

KW - hematopoietic stem cell

KW - kinase inhibitor

KW - leukemic stem cell

KW - transcription factor

UR - http://www.scopus.com/inward/record.url?scp=77956402272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956402272&partnerID=8YFLogxK

M3 - Article

C2 - 20812146

AN - SCOPUS:77956402272

VL - 13

SP - 548

EP - 558

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 5

ER -